SCHEMBL801694

SCHEMBL801694

Cc1ccccc1-c1cc(-c2ccccc2)nc(Nc2n[nH]c3ccccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.43
FADS1 O60427 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
TRPA1 O75762 1/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GSK3A P49840 2/20 0.40
GSK3B P49841 2/20 0.40
GRM4 Q14833 1/20 0.40
AGTR1 P30556 3/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802337 0.92 GRM4 (0.45) VCPFADS1TRPA1ALDH1A1SMN1; SMN2
SCHEMBL802027 0.88 FADS1 (0.46) VCPFADS1TRPA1ALDH1A1GSK3A
SCHEMBL805604 0.83 ACP1 (0.43) FADS1TDP1TRPA1GRM4CYP1A2
SCHEMBL802710 0.83 GSK3A (0.42) VCPFADS1TRPA1ALDH1A1SMN1; SMN2
SCHEMBL802348 0.83 FADS1 (0.40) FADS1TRPA1ALDH1A1GSK3AGSK3B
SCHEMBL801692 0.81 VCP (0.40) VCPTDP1ALDH1A1SMN1; SMN2NPC1
SCHEMBL802120 0.80 KDM4E (0.42) TDP1ALDH1A1GAACYP1A2CYP2C19
SCHEMBL802674 0.80 GSK3A (0.44) FADS1TRPA1ALDH1A1SMN1; SMN2NPC1
SCHEMBL802717 0.79 CYP1A2 (0.50) ALDH1A1CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL801700 0.79 FADS1 (0.43) FADS1TRPA1ALDH1A1GRM4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A VCP 4711/4885FADS1 1449/4885TDP1 1916/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 VCP 4775/4885FADS1 3442/4885TDP1 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.